APA (7th ed.) Citation

RL, T., MM, C., KZ, A., TJ, H., AKC, J., JA, S., . . . DK, O. (2022). Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease. Journal of general internal medicine, 37(13), 3380. https://doi.org/10.1007/s11606-021-07311-5

Chicago Style (17th ed.) Citation

RL, Tisdale, Cusick MM, Aluri KZ, Handley TJ, Joyner AKC, Salomon JA, Chertow GM, Goldhaber-Fiebert JD, and Owens DK. "Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease." Journal of General Internal Medicine 37, no. 13 (2022): 3380. https://doi.org/10.1007/s11606-021-07311-5.

MLA (9th ed.) Citation

RL, Tisdale, et al. "Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease." Journal of General Internal Medicine, vol. 37, no. 13, 2022, p. 3380, https://doi.org/10.1007/s11606-021-07311-5.